MediWound Ltd. — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2019. The filing is an annual Form 20-F, not a standalone quarterly filing; it does not provide a clear, separately reported Q4 income statement. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars, generally in thousands unless otherwise noted.
Business Context
MediWound is an Israeli biopharmaceutical company developing, manufacturing and commercializing enzymatic debridement products. Its marketed product, NexoBrid, is approved in the European Union, Israel, Argentina, South Korea, Russia and Peru for removal of eschar in adults with severe burns. EscharEx is in U.S. Phase 2 development for chronic and hard-to-heal wounds, while additional proteolytic-enzyme candidates are in preclinical development.
The company manufactures NexoBrid at its cGMP-certified facility in Yavne, Israel. North American development and commercialization rights were licensed to Vericel in May 2019. MediWound retains commercial rights outside North America and is responsible for development through potential U.S. BLA approval and product supply.
Key Financial Metrics
| Metric | 2018 | 2019 | Change |
|---|---|---|---|
| Total revenue | $3.4 million | $31.8 million | Up $28.4 million |
| Product sales | $3.2 million | $3.4 million | Up $0.2 million |
| Development-services revenue | — | $10.7 million | New category |
| License-agreement revenue | $0.2 million | $17.7 million | Primarily Vericel upfront payment |
| Gross profit | $1.3 million | $19.9 million | Up $18.6 million |
| Gross margin | Approximately 39% | Approximately 63% | Improved |
| Operating profit (loss) | $(4.0) million | $4.5 million | Improved by $8.5 million |
| Profit (loss) from continuing operations | $(5.7) million | $2.1 million | Improved by $7.7 million |
| Net profit (loss) | $(1.1) million | $5.0 million | Improved by $6.0 million |
| Basic and diluted earnings per share | $(0.04) | $0.18 | Improved |
| Cash flow from continuing operations | $(12.2) million | $9.9 million | Improved by $22.0 million |
| Cash, cash equivalents and short-term deposits | $23.6 million | $29.5 million | Up $5.8 million |
| Working capital | $27.8 million | $25.2 million | Down $2.6 million |
Revenue concentration was significant: Vericel contributed approximately 55% of 2019 revenue and BARDA approximately 34%; no other customer contributed at least 10%. U.S. customers represented $28.5 million, or approximately 90% of total revenue, compared with no U.S. revenue in 2018.
There was no long-term debt disclosed. The balance sheet included approximately $2.5 million of lease liabilities, $6.9 million of IIA grant liabilities, and $4.9 million of contingent consideration related to the former Teva share repurchase arrangement. Shareholders’ equity increased from $9.0 million to $15.2 million, while accumulated deficit declined from $130.7 million to $125.8 million.
Material Changes Versus 2018
- Vericel transaction: MediWound received a $17.5 million upfront payment in May 2019 and recognized it as license revenue. The agreement also provides for a potential $7.5 million payment upon U.S. BLA approval, up to $125 million in sales milestones, tiered royalties, and supply-related economics.
- BARDA revenue classification: Beginning in May 2019, $10.7 million of BARDA funding was classified as development-services revenue rather than as a reduction of research and development expense. This change materially affected revenue presentation and comparability.
- Profitability: The company moved from operating and net losses to operating profit of $4.5 million and net profit of $5.0 million. Management characterized the 2019 profit as substantially influenced by the one-time Vericel upfront payment.
- Research and development: Gross R&D expense fell 44% to $10.1 million, but net R&D expense after participations increased from $4.1 million to $5.0 million because of the BARDA classification change and higher subcontractor and personnel costs.
- Other expenses: General and administrative expense increased 38% to $5.2 million, primarily due to management changes and higher professional fees. Other expenses increased to $1.2 million, principally from one-time costs associated with the Vericel transaction.
- Cash flows: Continuing operating cash flow turned positive, primarily because of the Vericel upfront payment. Investing cash outflow was $5.7 million, including $0.8 million of capital expenditures and net investments in short-term deposits. Discontinued-operation cash outflows totaled approximately $2.8 million in connection with PolyHeal settlements and related matters.
- Accounting changes: The company adopted IFRS 16 leases in 2019, recognizing approximately $2.2 million of right-of-use assets and $2.5 million of lease liabilities at year-end.
Guidance, Outlook, Risks and Unusual Items
- U.S. regulatory plan: Management targeted submission of the NexoBrid BLA to the FDA by mid-2020, based on positive DETECT Phase 3 results and 12-month follow-up data. Approval was not assured, and 24-month safety data were expected to be submitted as a post-approval commitment if approval occurred.
- Clinical development: The pediatric CIDS Phase 3 study was ongoing, with interim results expected in the first half of 2022 and final results in the first half of 2023. A U.S. Phase 2 adaptive-design study of second-generation EscharEx for venous leg ulcers began in December 2019, with an interim assessment expected by the end of 2020.
- BARDA dependence: The two BARDA contracts had potential aggregate funding of up to $196 million, of which approximately $43.0 million had been recorded through December 31, 2019. The initial BARDA NexoBrid procurement was valued at $16.5 million, with deliveries expected during 2020. BARDA could terminate the contracts at its discretion, and options for additional funding or procurement were not assured.
- Liquidity outlook: Management stated that existing cash, cash equivalents and short-term deposits were sufficient to satisfy liquidity requirements for at least the next 24 months. Nevertheless, the company expected significant expenses and operating losses for the foreseeable future and retained the possibility of future equity, debt or partnership financing.
- Manufacturing and supply concentration: MediWound relies on a single Yavne manufacturing facility and a sole supplier, Challenge Bioproducts Corporation, for bromelain SP. The company estimated that existing bromelain inventory could support approximately two years of full-capacity operations, but warned that supply disruption, regulatory issues or facility damage could materially affect production.
- Capacity expansion: The company planned to expand manufacturing capacity, with estimated costs of approximately $8 million to $10 million and qualification targeted by the end of 2022, subject to regulatory audits and successful implementation.
- Unusual and nonrecurring items: The 2019 results included the $17.5 million Vericel upfront payment, $2.9 million of profit from the discontinued PolyHeal operation, approximately $1.7 million of expense from revaluation of contingent consideration, and one-time costs associated with management changes and the Vericel transaction.
- Contingencies: MediWound agreed to pay Teva 15% of recognized NexoBrid revenue after January 1, 2019, up to an aggregate $10.2 million, and agreed to indemnify Teva for certain PolyHeal-related claims received by December 31, 2023, up to $10.2 million.
- Principal risks: Key risks include failure or delay in FDA approval, dependence on NexoBrid and BARDA, uncertain EscharEx development, market acceptance and reimbursement, manufacturing and single-supplier disruption, intellectual-property challenges, foreign-exchange exposure, Israeli geopolitical risk, regulatory compliance, and potential future dilution.
Investor Verification Checklist
- Verify how much of 2019 revenue and profit was nonrecurring, particularly the Vericel upfront payment and PolyHeal discontinued-operation gain.
- Reconcile the change in BARDA accounting classification and distinguish recurring development-services revenue from reimbursement of R&D expenses.
- Confirm the status and timing of the NexoBrid U.S. BLA, FDA review, potential approval milestones and Vericel commercialization obligations.
- Track actual BARDA procurement deliveries, payments, contract options and any termination or modification notices.
- Assess whether cash resources remain sufficient as EscharEx, pediatric NexoBrid development, manufacturing expansion and commercialization costs increase.
- Review exposure to the single bromelain SP supplier and the Yavne manufacturing facility, including the outcome of required cGMP inspections.
- Monitor the Teva royalty obligation, IIA royalty liability, PolyHeal-related indemnity and other contingent commitments.
- Evaluate customer concentration, product-sales growth excluding licensing and BARDA revenue, and the sustainability of gross margins.
- Consider potential dilution from the company’s $125 million shelf registration and outstanding options and RSUs.